PDE6B and Leber congenital amaurosis: Many other retinal gene therapy clinical trials are currently ongoing or recruiting, targeting RPGR and PDE6B-associated RP, CNGA3 and CNGB3-associated achromatopsia, RPE65-associated LCA, RS1-associated x-linked retinoschisis, and ND4-associated optic neuropathy5.